Phibro Animal Health Corporation (Nasdaq: PAHC) has successfully acquired Zoetis Inc.’s (NYSE: ZTS) portfolio of medicated feed additives and certain water-soluble products, enhancing its cattle health offerings. This acquisition aligns with Phibro’s dedication to advancing sustainable solutions in animal health and nutrition, particularly for cattle, while broadening its presence across key livestock sectors.
With this new product range, Phibro strengthens its position in supporting optimal cattle health, aiding producers in disease prevention, nutritional improvement, and maintaining high standards of care. These additions integrate seamlessly into Phibro’s existing lineup, which already includes robust offerings in vaccines, nutritional specialties, and mineral-based health solutions.
The portfolio brings over 37 product lines available across roughly 80 countries, along with six manufacturing facilities in the U.S., Italy, and China, and a team of 300+ employees focused on production and distribution. Announced on April 28, 2024, this acquisition is expected to bolster Phibro’s profitability, contribute to an enhanced EBITDA margin, and positively impact its Adjusted Earnings Per Share. Financial updates will be shared during the Q1 earnings call on November 7.
The expanded portfolio not only adds value for Phibro’s cattle-focused customers by increasing the range of animal health solutions but also supports safer, more sustainable food production for consumers. It diversifies Phibro’s revenue base, creating a foundation for further investment into high-growth areas of animal health.
